E1505: Adjuvant Chemotherapy +/- Bevacizumab For Early Stage Nsclc-Outcomes Based On Chemotherapy Subsets.

8507Background: Adjuvant chemotherapy (chemo) for resected early stage NSCLC provides modest survival benefit. E1505 offers the first opportunity to study 4 modern cisplatin-based regimens in the adjuvant setting in the context of a single trial. As previously reported from this trial, the addition of bevacizumab (B) to adjuvant chemo failed to improve the primary endpoint of overall survival (OS HR=0.99; 95% CI: 0.82-1.19, p=0.91) or disease free survival (DFS HR=0.99; 95%CI: 0.85-1.15, p=0.89). Here we explore outcomes by chemo regimen utilized. Methods: Patients (pts) with resected early stage NSCLC, stratified by stage, histology, sex, and chemo option, were randomized 1:1 to chemo alone or chemo with B (15 mg/kg every 3 weeks for up to 1 year). Chemo consisted of a planned 4 cycles of every 3-week cisplatin (75 mg/m2 d1) with investigator’s choice of vinorelbine (V) (30 mg/m2 d1,8), docetaxel (D) (75 mg/m2 d1), gemcitabine (G) (1200 mg/m2 d1,8), or pemetrexed (P) (500 mg/m2d1). P was added in 2009 fo...